Ionis Pharmaceuticals, Inc.
IONS
Xếp hạng trong cổ phiếu
#2547
Founded in 1989 and headquartered in Carlsbad, California, Ionis... Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapies within the United States. Its commercial portfolio includes three key medications: SPINRAZA, prescribed for spinal muscular atrophy (SMA) in both children and adults; TEGSEDI, an injectable treatment targeting polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adult patients; and WAYLIVRA, which addresses familial chylomicronemia syndrome and familial partial lipodystrophy. Ionis also maintains a robust pipeline, with several drug candidates currently in Phase 3 clinical trials. These include Eplontersen, a monthly self-administered subcutaneous injection designed for all forms of TTR amyloidosis; Olezarsen, intended for individuals with severe hypertriglyceridemia (SHTG); Donidalorsen, for patients suffering from hereditary angioedema; ION363, aimed at amyotrophic lateral sclerosis (ALS); Pelacarsen, developed for those with established cardiovascular disease and elevated lipoprotein(a); and Tofersen, which works by inhibiting the production of superoxide dismutase 1. Beyond these late-stage assets, the company is actively researching treatments for metabolic, infectious, renal, and ophthalmic diseases, as well as various types of cancer. The firm engages in significant collaborations, notably a strategic partnership with Biogen Inc. Additionally, it holds licensing and collaboration agreements with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc.
Giá cổ phiếu
$45.01
Vốn hóa thị trường
$7.48B
Thay đổi (1 ngày)
-0.87%
Thay đổi (1 năm)
-37.18%
Quốc gia
US
Giao dịch Ionis Pharmaceuticals, Inc. (IONS)
Danh mục
Healthcare
Doanh thu của Ionis Pharmaceuticals, Inc. (IONS)
Doanh thu vào Jun 2026 TTM: $873.76M
Theo các báo cáo tài chính gần đây của Ionis Pharmaceuticals, Inc., doanh thu hiện tại của công ty (TTM) là $873.76M. Trong năm 2023, công ty đạt doanh thu $787.65M tăng so với doanh thu năm 2022, là $587.37M. Doanh thu là tổng số tiền công ty tạo ra từ việc bán hàng hóa hoặc dịch vụ. Không giống như lợi nhuận, doanh thu không trừ chi phí.
Lịch sử doanh thu của Ionis Pharmaceuticals, Inc. từ 2000 đến 2026
Doanh thu vào cuối mỗi năm
| Năm | Doanh thu | Thay đổi |
|---|---|---|
| 2026 (TTM) | $873.76M | 23.91% |
| 2024 | $705.14M | -10.48% |
| 2023 | $787.65M | 34.10% |
| 2022 | $587.37M | -27.53% |
| 2021 | $810.46M | 11.13% |
| 2020 | $729.26M | -35.04% |
| 2019 | $1.12B | 87.20% |
| 2018 | $599.67M | 16.63% |
| 2017 | $514.18M | 37.93% |
| 2016 | $372.78M | 31.40% |
| 2015 | $283.70M | 32.47% |
| 2014 | $214.16M | 45.41% |
| 2013 | $147.29M | 44.33% |
| 2012 | $102.05M | 2.99% |
| 2011 | $99.09M | -8.65% |
| 2010 | $108.47M | -10.80% |
| 2009 | $121.60M | 13.44% |
| 2008 | $107.19M | 83.72% |
| 2007 | $58.34M | 292.65% |
| 2006 | $14.86M | -62.98% |
| 2005 | $40.13M | -5.84% |
| 2004 | $42.62M | -14.73% |
| 2003 | $49.99M | -37.65% |
| 2002 | $80.18M | 50.51% |
| 2001 | $53.27M | 43.00% |
| 2000 | $37.26M | 0.00% |
Doanh thu của các công ty hoặc đối thủ tương tự
| Công ty | Doanh thu | Chênh lệch doanh thu | Quốc gia |
|---|---|---|---|
| $12.62B | 1,344.83% |
US
|
|
| $2.23B | 154.99% |
US
|
|
| $15.74B | 1,701.91% |
AU
|
|
| $6.02B | 589.12% |
NL
|
|
| - | - |
CH
|
